Severe early-childhood-onset retinal dystrophy
MONDO:0009549Severe early childhood onset retinal dystrophy (SECORD) is an inherited retinal dystrophy, characterized by a severe congenital night blindness, progressive retinal dystrophy and nystagmus. Best corrected visual acuity can reach 0.3 in the first decade of life and can pertain well into the second decade of life. Blindness is often complete by the age of 30 years. An overlap with Leber congenital amaurosis (LCA) occurs when patients are characterized by their visual acuity and panretinal dystrophy.
Also known as: EOSRD, SECORD, Stargardt disease type 1, early-onset severe retinal dystrophy, STGD1, Stargardt disease 1, Stgd, fundus flavimaculatus
37 clinical trials for this condition and its sub-types, 10 tagged with Severe early-childhood-onset retinal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Modified vitamin a pill tested against inherited blindness
Disease control OngoingResearchers are testing whether a daily pill called ALK-001 can slow the progression of Stargardt disease, a rare inherited condition that causes vision loss in children and young adults. The trial enrolls people aged 8 and older who have a clinical diagnosis of Stargardt disease…
Phase 2 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Vitamin a derivative eyed to halt inherited blindness
Disease control OngoingResearchers are testing a daily oral drug called ALK-001 in people aged 8 to 70 with Stargardt disease, an inherited condition that causes progressive vision loss. The trial compares ALK-001 to a placebo over 24 months to see if the drug is safe and can slow damage to the retina.…
Phase 2 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New hope for rare eye disease: drug trial targets vision loss
Disease control OngoingThis study tests a drug called tinlarebant in 60 people with Stargardt disease, a genetic condition that causes vision loss. The goal is to see if the drug can slow damage to the retina and preserve eyesight. Participants take the drug or a placebo, and researchers measure change…
Phase 2/3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC